Yu Hao, Peng Yizhong, Wu Zhipeng, Wang Minjie, Jiang Xiaobing
Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Transl Cancer Res. 2022 Jul;11(7):2249-2261. doi: 10.21037/tcr-21-2557.
MiR-193b has been widely investigated in the last few years and an aberrant association has been observed between its expression levels and the prognosis of several human malignancies. We performed a meta-analysis to evaluate the prognostic effect of miR-193b on human cancers.
PMC, PubMed, Web of Science (WOS), Embase in English and VIP, Wanfang, SinoMed and the China National Knowledge Infrastructure (CNKI) in Chinese were searched up to May 16, 2020. The pooled hazard ratio (HR) with a 95% confidence interval (CI) was calculated to evaluate its prognosis in human cancers. Also, the pooled odd ratios and the relevant 95% CIs were computed to assess the association of miR-193b levels and clinicopathological characteristics of cancer patients.
In overall analysis, a significant association was identified between miR-193b levels and overall survival (HR =0.77, 95% CI: 0.64-0.92), but this association was not significant in the random pooling model. Then, two outliers were identified through sensitivity analysis. After removing outliers, the significant association was identified with random pooling model (HR =0.45, 95% CI: 0.30-0.69). In addition, the significance exited among Asian (HR =0.45, 95% CI: 0.28-0.74), studies with the sample size (≥100) (HR =0.39, 95% CI: 0.27-0.56) and sample size (<100) (HR =0.51, 95% CI: 0.28-0.92), Newcastle-Ottawa scale (NOS) scores (≥8) (HR =0.44, 95% CI: 0.30-0.67) and NOS scores (<8) (HR =0.45, 95% CI: 0.25-0.80) and patients of non-digestive carcinoma (HR =0.35, 95% CI: 0.24-0.52), digestive carcinoma (HR =0.54, 95% CI: 0.31-0.92), non-urogenital carcinoma (HR =0.52, 95% CI: 0.33-0.82) or urogenital carcinoma (HR =0.28, 95% CI: 0.16-0.50). Lower expression of miR-193b was found to be related to larger tumor size and the potential of lymph node metastasis and distance metastasis.
We have demonstrated that miR-193b serves as an ideal biomarker in the cancer prognosis for Asian patients, and the low expression levels of miR-193b is significantly associated with poor overall survival rates in various human malignancies. Moreover, the patients with lower miR-193b tend to develop the cancers with higher potential of metastasis.
近年来,miR-193b受到广泛研究,其表达水平与多种人类恶性肿瘤的预后之间存在异常关联。我们进行了一项荟萃分析,以评估miR-193b对人类癌症的预后影响。
检索截至2020年5月16日的英文数据库(PubMed、Web of Science、Embase、PMC)以及中文数据库(维普、万方、中国生物医学文献数据库、中国知网)。计算合并风险比(HR)及95%置信区间(CI)以评估其在人类癌症中的预后情况。同时,计算合并比值比及相关95%CI以评估miR-193b水平与癌症患者临床病理特征的关联。
在总体分析中,miR-193b水平与总生存期之间存在显著关联(HR = 0.77,95%CI:0.64 - 0.92),但在随机效应模型中该关联不显著。随后,通过敏感性分析确定了两个离群值。剔除离群值后,随机效应模型显示出显著关联(HR = 0.45,95%CI:0.30 - 0.69)。此外,在亚洲人群(HR = 0.45,95%CI:0.28 - 0.74)、样本量≥100的研究(HR = 0.39,95%CI:0.27 - 0.56)、样本量<100的研究(HR = 0.51,95%CI:0.28 - 0.92)、纽卡斯尔-渥太华量表(NOS)评分≥8的研究(HR = 0.44,95%CI:~0.30 - 0.67)、NOS评分<8的研究(HR = 0.45,95%CI:0.25 - 0.80)以及非消化系统癌患者(HR = 0.35,95%CI:0.24 - 0.52)、消化系统癌患者(HR = 0.54,95%CI:0.31 - 0.92)、非泌尿生殖系统癌患者(HR = 0.52,95%CI:0.33 - 0.82)或泌尿生殖系统癌患者(HR = 0.28,95%CI:0.16 - 0.50)中均存在显著性。发现miR-193b低表达与更大的肿瘤大小、淋巴结转移及远处转移潜能相关。
我们证明了miR-193b是亚洲患者癌症预后的理想生物标志物,miR-193b低表达与多种人类恶性肿瘤的总生存率低显著相关。此外,miR-193b水平较低的患者往往更容易发生转移潜能较高的癌症。